Du är här


Swedish Orphan Biovitrum AB (publ): Sobi publishes its report for the fourth quarter and full year 2015

Swedish Orphan Biovitrum AB (publ)(Sobi(TM)) today announced its results for
the fourth quarter and full year 2015. Revenues for the full year totalled
SEK 3,228 M (2,607), an increase of 24 per cent compared to previous year.
Revenues for the fourth quarter were 15 per cent higher year-on-year and the
product revenues grew 21 per cent, with Orfadin® (nitisinone) and Kineret®
(anakinra) delivering strong performance.

Business Summary Q4 2015

* Elocta® (efmoroctocog alfa) approved in Europe for the treatment of
haemophilia A
* New data showed that Elocta and Alprolix® (rFIXFc) may reduce target joint
bleeds in people with haemophilia A and B
* Sobi and Biogen initiated deliveries of largest ever donation of
haemophilia therapy to World Federation of Hemophilia for patients in the
developing world
* Xiapex® (collagenase clostridium histolyticum) approved in EU for the
treatment of two Dupuytren's contracture cords concurrently

Financial Summary Q4 2015 (Q4 2014)

* Total revenue was SEK 814 M (705), an increase of 15 per cent (9 per cent
at constant currencies)
* Product revenue was SEK 698 M (575), an increase of 21 per cent (13 per
cent at constant currencies)
* Gross margin was 64 per cent (60)
* EBITA was SEK 90 M (38)

Financial Summary FY 2015 (2014)

* Total revenue was SEK 3,228 M (2,607), an increase of 24 per cent (14 per
cent at constant currencies)
* Product revenue was SEK 2,568 M (1,989), an increase of 29 per cent (18 per
cent at constant currencies)
* Gross margin was 62 per cent (59)
* EBITA was SEK 433 M (-43)
* Ended the year with a cash position of SEK 904 M (519)

"2015 was a pivotal year for Sobi. We delivered strong financial results,
welcomed many new colleagues, expanded our geographic footprint and received
important regulatory approvals for our products," said Sobi's CEO and
President Geoffrey McDonough. "The approval of Elocta in particular - our
extended half-life haemophilia A treatment - has the potential to create a
true paradigm shift in the treatment of and protection against bleeding and
joint damage for people with haemophilia A. We are focused on expanding our
reach on the foundation of these achievements going forward."
| Financial Summary |
| Q4 Q4 Full year Full year |
| Amounts in SEK M 2015 2014 Change 2015 2014 Change |
| Total revenues 814 705 15% 3 228 2 607 24% |
| Gross profit 520 427 22% 2 007 1 548 30% |
| Gross margin 64% 60% 62% 59% |
| EBITA1 90 38 >100% 433 -43 >100% |
| EBITA excluding write-offs 90 63 41% 433 307 41% |
| EBIT (Operating profit/loss) 17 -33 >100% 146 -325 >100% |
| Profit/loss for the period -9 -17 48% 68 -268 >100% |
| |
| 12014 FY includes write-offs relating to Kiobrina® of SEK 325 M (Q1) and |
| Multiferon of SEK 25M (Q4). |
Outlook 2016[1]

For 2016, Sobi expects total revenues for the full year to be in the range of
SEK 4,300 to 4,500 M, and gross margin is expected be in the range of 66 to
68 per cent. EBITA for the full year is expected to be in the range of SEK
700 to 800 M.


Sobi's report for the fourth quarter and full year 2015 can be found

About Sobi(TM)

Sobi is an international speciality healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primary
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products for partner companies
across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed
on NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

| Media relations Investor relations |
| Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations |
| T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| oskar.bosson@sobi.com jorgen.winroth@sobi.com |
Sobi announces the information set out in this press release pursuant to the
Swedish Securities Market Act. The information was submitted for publication
at 08:00 CET on 26 February 2016.
---------------------------------------[1]2016 will be impacted by a one-time credit for Elocta estimated to be SEK
300 to 325 M. This one-time credit will be reported in the Profit and Loss
statement but will not impact cash. Operating expenses includes Sobi share of
ongoing costs for Elocta, estimated to be SEK 200 to 250 M. The outlook
excludes the impact of an anticipated Alprolix approval and launch in 2016.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.